SPRING HOUSE, PA — Third Arc Bio Inc. has closed a $52 million extension of its Series A financing, adding fresh firepower to a previously announced $165 million raise as the biotech accelerates its push into oncology and immune-inflammatory diseases.
The latest round was led by new investor Andreessen Horowitz, marking a high-profile endorsement of the company’s approach to highly targeted immune modulation. Founding investor Omega Funds also participated, alongside Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn. Inc., accounts advised by T. Rowe Price Associates, Inc., Marshall Wace, Hillhouse Investment, Galapagos NV, AbbVie Ventures, and Alderline Group.
As part of the financing, Andreessen Horowitz General Partner Jorge Conde has joined Third Arc Bio’s board of directors. The company said proceeds will be used to advance its inflammation and immunology portfolio and move additional oncology programs into clinical development.
Conde said the investment reflects a shift in how next-generation biologics are being designed. He said Third Arc is focused on precise immune modulation, moving beyond systemic exposure toward therapies engineered to deliver controlled biological effects at sites of disease, combining platform innovation with a team experienced in translating complex immunology into approved medicines.
Founded in 2022 with seed financing from Omega Funds, Third Arc Bio has built a pipeline centered on multispecific antibody platforms. Its lead program, ARC101, is a bispecific T-cell engager targeting CLDN6 and is currently in Phase 1 dose escalation studies in patients with advanced solid tumors.
Chief Executive Officer Peter F. Lebowitz said the additional capital allows the company to keep multiple programs moving in parallel. He said the strategy is designed to accelerate proof-of-concept generation while advancing next-generation assets into first-in-human studies, with the goal of delivering new therapies for patients with significant unmet medical needs.
The financing extends a period of rapid momentum for Third Arc Bio, as investor interest remains strong in precision immunology platforms that aim to improve both efficacy and safety in cancer and immune-mediated diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.